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ABSTRACT 
A simple, accurate, economical and precise reverse phase high performance liquid chromatographic (RP-HPLC) method has been developed for 
simultaneous estimation of Metformin hydrochloride and Glipizide in bulk and pharmaceutical dosage form. The separation  of Metformin 
hydrochloride and Glipizide was achieved by  using Cosmosil C 18 (250 mm × 4.6 ID, particle size-5 micron) column as stationary phase with  
the mobile phase comprising of methanol and water (60:40 ,pH 3 adjusted with ortho-phosphoric acid) in an isocratic mode and flow rate of 0.8 
ml/min with UV detection at 226 nm. The retention time of Metformin hydrochloride and Glipizide were found to be 4.159 min and 5.571 min 
respectively. The proposed method was validated according to ICH guidelines for the parameters like linearity, accuracy, precision, percent 
recovery, robustness, ruggedness, limit of detection and limit of quantitation. The % RSD is found to be less than 2 % and the tailing factor for 
both the drugs are found to be less than 2. The number of therotical plates for Metformin hydrochloride and Glipizide were found to be more 
than 2000.All validation parameters were within the acceptable range. The developed method was successfully applied for the estimation of 
Metformin hydrochloride and Glipizide in bulk and pharmaceutical dosage forms. 
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INTRODUCTION 
Metformin [Figure 1] (Molecular formula-C4H11N5) is 1-
carbamimidamido-N,N-
dimethylmethanimidamide.Metformin is the compound  
belongs to the class of  organic compounds known as 
biguanides.Biguanides are the organic compounds 
containing two N-linked guanidine. 
Metformin is a antihyperglycemic agent used for the 
treatment of non-insulin-dependent diabetes mellitus 
(NIDDM).It improves the glycemic control by decreasing 
hepatic glucose production, decreasing glucose absorption 
and increasing the insulin-mediated glucose uptake. 
Metformin is the only oral anti-diabetic agent that is not 
associated with weight gain. Metformin may induce weight 
loss and it is the drug of choice for the obese NIDDM patients. 
[1]  
Glipizide [Figure 2]     (Molecular formula- C21H27N5O4S) is a 
N-[2-(4-{[(cyclohexylcarbamoyl) amino] sulfonyl}] phenyl) 
ethyl]-5-methylpyrazine-2-carboxamide.lipizide is an oral 
hypoglycemic agent which is rapidly absorbed and 
metabolised completely.Glipizide belongs to the class of 
organic compounds known as benzenesulfonamides. 
Benzenesulfonamides are the organic compounds containing 
a sulfonamide group which is S-linked to the benzene ring. 
Glipizide is a second generation sulfonylurea and it is used 
with diet to lower blood glucose in patients with type-II 
diabetes mellitus..Glipizide lowers the blood glucose level 
acutely by stimulating the release of insulin from the 
pancreas,this effect is dependent on functioning of beta cells 
in pancreatic islets. [2]. 
 
Fig.1: Chemical structure of Metformin Hydrochloride 
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Fig.2: Chemical structure of Glipizide 
Literature survey of Metformin Hydrochloride and Glipizide 
revealed few methods based on Chromatography [3-9] have 
been have been reported for the determination of both drugs 
in single and combined dosage forms.The present work 
describes the development and validation as per ICH 
guidelines [10] of reverse phase-high performance liquid 
chromatographic method ( RP-HPLC method) , which can 
quantify these components simultaneously. 
MATERIALS AND METHODS 
Instrument and equipment 
Chemicals and Reagents 
Pure samples of Metformin Hydrochloride and Glipizide 
were provided as a gift sample by Wintech Pharmaceuticals 
Pvt.Ltd., Sinner. The commercial pharmaceutical preparation 
Dibizide –M containing 500 mg Metformin Hydrochloride 
and 5 mg Glipizide respectively (manufactured by Micro Labs 
Ltd.) were procured from local pharmacy. Methanol HPLC 
grade, ortho-phosphoric acid (OPA)HPLC grade were 
procured from Finar chemicals,Ahmedabad,Gujrat and Merk 
Chemicals, Mumbai respectively.HPLC grade water was 
obtained from Milli-Q water purification system ( 
Millipore,Milford,USA). 
 Instrumentation and software 
 A HPLC (Binary Gradient system, Model: HPLC 3000 series) 
consisting of P-3000-M Reciprocating pump (40 MPa), UV-
VIS detector (Model: series 3000-M), Cosmosil C-18 (250mm 
× 4.6 ID, particle size-5 micron) and a sample injector system 
with a 20 µl sample loop and HPLC workstation software 
on;Ultrasonicator (Wenser Ultra Sonicator,Model:WUC-4L). 
Chromatographic System 
The chromatographic column used was C-18 (250 mm × 4.6 
ID, particle size-5 micron). Mobile phase consists of 
methanol and water (60:40, pH 3 adjusted with ortho-
phosphoric acid).The flow rate of mobile phase was kept at 
0.8 ml/min and the column temperature was maintained at 
ambient and the chromatogram was monitored at 226 nm. 
The injection volume was monitored at 20µl. 
Identification of Metformin Hydrochloride and Glipizide 
Melting point determination 
Melting point was determined using digital melting point 
apparatus with one end open capillary method. 
 
Table 1: Melting point determination 
Sr.No. Name Melting Point Standard Value Melting Point Observed Value 
1. Metformin Hydrochloride 222°-226°C 220°-222°C 
2. Glipizide 208°-209°C 208°-210°C 
 
Determination of Wavelength Maxima 
The standard solution of both the drugs was scanned 
between 400 nm-200nm.The overlain spectrum of both the 
drugs was recorded. From the overlain spectrum, 226 nm 
(λmax of Glipizide) and 238.5 nm (λmax of Metformin 
Hydrochloride) were selected for estimation of drugs and the 
isobestic point was found to be at 226nm and it is shown in 
figure 3. 
 
  
 
                          
Figure 3: Isobestic point of Metformin HCl and Glipizide 
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Table No.2: Wavelength maxima of Metformin HCl and Glipizide 
Sr.No. Name of the Sample Wavelength Absorbance 
1. Metformin Hydrochloride 238.5 1.0792 
2. Glipizide 226 1.3130 
3. Isobestic point of Metformin HCl and Glipizide 226 1.3102 
 
Preparation of mobile phase 
 Pipette out 60 ml of methanol and 40 ml of 2 % OPA solution 
in HPLC grade water (to adjust the pH 3) and Sonicate 5 
minutes. 
Preparation of standard stock solutions 
Accurately weighed 10 mg of pure drugs i.e. Metformin 
Hydrochloride and Glipizide dissolved individually in 10 ml 
of mobile phase; this gives 1000 ppm stock solutions of 
Metformin Hydrochloride and Glipizide (Stock-1) .Standard 
calibration solutions of Metformin Hydrochloride and 
Glipizide having concentration in the range of 100 µg/ml-
500µg/ml and 1µg/ml-5µg/ml respectively were prepared 
by diluting stock solution (Stock-1) with mobile phase. 
Analytical method validation  
Validation is documented evidence, which provide a high 
degree of assurance for specific method. Validation is 
analytical process by which it is established by laboratory 
studies that the performance characteristics of the procedure 
meet the requirement for intended analytical application  
Linearity   
The linearity of an analytical method is its ability to elicit test 
results that are directly, or by a well‐defined mathematical 
transformation, proportional to the concentration of analyte 
in sample within a given range. 
Procedure for preparation of sample  solution for 
determination of Linearity 
 Linearity was established by calibration curve of five 
standard drug concentration. From stock solution , pipette 
out  1ml,2ml,3ml,4ml and 5ml  Metformin hydrochloride 
solution and 0.01 ml,0.02 ml,0.03 ml,0.04 ml, 0.05 ml 
Glipizide solution and make up  the final volume upto the 
10ml with the mobile phase.It gives 100 ppm,200 ppm,300 
ppm,400 ppm and 500 ppm solutions of Metformin 
hydrochloride and 1 ml,2 ml,3 ml,4 ml and 5ml solutions of 
Glipizide respectively .Calibration curve was constructed 
between concentration and peak area.  
Accuracy  
The accuracy of an analytical method is the closeness of test 
results obtained by that method to the true value. The 
accuracy of an analytical method is determined by applying 
the method to analyzed samples to which known amounts of 
analyte have been added. The accuracy is calculated from the 
test results as the triplicates sample preparation.  
Procedure for preparation of sample solution for 
determination of Accuracy  
The accuracy was determined by using data obtained from 
precision study and determined from the calibration curve. 
Accuracy is done by three level i.e. 100 ppm,300ppm and 
500 ppm of metformin hydrochloride and 1ppm,3ppm and 5 
ppm of Glipizide .,etc. And the concentration for the accuracy 
determination is taken 100µg/ml of Metformin 
hydrochloride and 1 µg/ml of Glipizide respectively, from the 
stock solution .Find out the Area, Assay and % RSD of 
sample. 
Precision 
The precision of an analytical procedure represents the 
nearness of agreement between a series of measurements 
got from multiple sampling of the same homogenous sample 
under the similar analytical conditions and it is divided into 
3 categories.    
Repeatability: - Precision under same operating conditions, 
same analyst over a short period of time.   
Intermediate precision: - Method is tested on multiple 
days, instruments, analysts etc.  
Reproducibility: -Inter-laboratory studies.   
 The ICH guidelines suggest that repeatability should be 
conformed duly utilizing at least 9 determinations with 
specified range for the procedure (e.g., three concentrations 
/ three replicates each) or a minimum of 6 determinations at 
100 % of the test concentration.  
Procedure for preparation of sample solution for 
determination of Precision 
The  Precision or repeatability of the method was 
determined by assuming two standard solutions from the 
stock solution 3ml of Metformin hydrochloride and 0.03 ml 
of Glipizide pipette out and dilute up to the 10 ml with 
mobile phase at conc.300µg/ml. and 3µg/ml.The 
reproducibility of proposed method was determined by 
performing drug assay at different time intervals on same 
day (intra-day precision) and on two different days (inter-
day precision).Result were recorded to calculate mean, SD, 
%RSD as per ICH guidelines. 
% Recovery  
The recovery of an analytical method is determined by 
applying the method to analyzed samples to which known 
amounts of analyte have been added. The Recovery is 
calculated from the test results as the percentage of analyte 
recovered by the assay.  
Procedure for preparation of sample solution for 
determination of % Recovery  
The Stock solution equivalent to 300%, 400% and 500% 
were prepared by using standard stock solution. From the 
result, % recovery was calculated. Injected standard 
preparation and sample preparations of recovered solutions 
into the HPLC and measure the peak responses. Amount of 
drug recovered was calculated. 
Robustness  
It is the measure of capacity of the method to remain 
unaffected by small but deliberate variation in method 
parameter and provides an indication of its reliability under 
normal usage.  
Determination  
The robustness of an analytical procedure is a measure of its 
capacity to remain unaffected by small, but deliberate 
variations in method parameters and provides an indication 
of its reliability during normal usage. E.g. flow rate, 
concentration, run time etc. 
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Limit of Detection (LOD) 
LOQ is determined by the analysis of samples with known 
concentration of analyte and by establishing that minimum 
level at which the analyte can reliably detected, but not 
necessarily quantitated as precise value, under the stated 
experimental conditions. The detection limit is generally 
expressed in the concentration of analyte (ppm) in the 
sample.   
The formula for calculating LOD is LOD = 3.3 δ/S   
Where δ = standard deviation of intercepts of calibration 
curves.             
            S = the slope of linearity plot.   
Limit of Quantitation (LOQ)   
Limit of quantitation is the least concentration of drug in a 
sample which is estimated with appropriate precision and 
accuracy under the affirmed experimental conditions.   
The formula for calculating LOQ is LOQ = 10 δ/S 
Where δ = standard deviation of response.              
            S = Mean of slopes of the calibration curves.   
System Suitability Parameter  
1) Resolution  
Resolution value should be greater than 1.75. This parameter 
is applicable only when there is a combination of two 
samples. In case of single sample it will show zero „0‟ value.  
2) Theoretical Plates  
Number of theoretical plates should be greater than 2000. It 
indicates the efficiency of column. 
3) Tailing / Asymmetry factor  
Value of asymmetry factor should be less than 2.  
Acceptance criteria  
• Asymmetry of both the analytes peak in standard should 
not be more than 1.0  
• Theoretical plates of both the analytes peak in standard 
should not be less than 2000  
• Relative Standard Deviation for five replicates injections of 
both the standard preparation should not be more than 2.0%  
Method development  
All the trials are shown in table 1 and selected method 
chromatogram is shown in fig.4. 
Selection of Mobile Phase   
         
Table 3: Observation and Remarks of the Method Development 
S.N. Trials Taken Observation  Remark 
1 Methanol: Water (70:30),pH 3 adjusted with OPA  shows bad peak shape Not Satisfactory 
2 Methanol: Water (60:40),pH 3 adjusted with OPA Shows sharp peak and stable Retention time Satisfactory 
 
 
Figure 4: Chromatogram for selected method 
 
Table 4: Final Chromatographic conditions 
Column Cosmosil C18 (250mm × 4.6 ID, Particle size:-5 micron) 
Flow rate 0.8 ml/min 
Wavelength 226 nm 
Injection volume 20 µL 
Run time 8.01 min 
Mobile phase Methanol: Water (60:40), pH 3 adjusted with (2 %) OPA 
Elution type Isocratic elution 
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METHOD VALIDATION  
The developed method for Metformin Hydrochloride and Glipizide was validated as per ICH guidelines.  
Accuracy  
Table 5: Result and statistical data of accuracy for Metformin Hydrochloride 
      Standard Deviation Accuracy Precision 
Sr.No. Conc. Area Mean SD %SD %RSD 
  100 922877         
1 100 927432 925256.3333 2284.319665 0.2468851 0.246885061 
  100 925460         
              
  300 2880002         
2 300 2871216 2874571 4746.659984 0.1651259 0.165125856 
  300 2872495         
  
   
      
  500 4775306         
3 500 4764993 4773503 7767.070168 0.1627122 0.162712167 
  500 4780210         
              
 
Table 6: Result and statistical data of accuracy for Glipizide 
      Standard Deviation Accuracy Precision 
Sr.No. Conc. Area Mean SD %SD %RSD 
  1 137246         
1 1 136619 137423.3333 906.1094489 0.6593563 0.659356331 
  1 138405         
              
  3 405362         
2 3 401759 404547 2482.931533 0.613756 0.613756012 
  3 406520         
              
  5 638980         
3 5 633467 635800.6667 2852.131893 0.448589 0.448589006 
  5 634955         
              
 
% Recovery 
A] % Recovery of Metformin Hydrochloride- 
Table 7: Result and Statistical data of % Recovery of Metformin Hydrochloride 
Sr. 
No. 
Level (%) Conc. Of API 
spiked 
(µg/ml) 
Conc. Of 
Sample 
solution 
(µg/ml) 
Total 
Concentrati
on (µg/ml) 
Area of 
Standard 
Area of 
Sample 
% Recovery 
1 50 % 100 200 300 2880002 2868459 99.59 
2 100 % 100 300 400 3871538 3872852 100.03 
3 150 % 100 400 500 4775306 4751550 99.50 
 
B] % Recovery of Glipizide- 
Table 8: Result and Statistical data of % Recovery of Glipizide 
Sr. 
No. 
Level (%) Conc. Of API 
spiked 
(µg/ml) 
Conc. Of 
Sample 
solution 
(µg/ml) 
Total 
Concentrati
on (µg/ml) 
Area of 
Standard 
Area of 
Sample 
% Recovery 
1 50 % 1 2 3 405362 401869 99.13 
2 100 % 1 3 4 522726 526067 100.63 
3 150 % 1 4 5 638980 632059 98.91 
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Precision 
1. Intra- day Precision:- 
A. Intra- day Precision for Metformin hydrochloride:- 
Table 9:  Result of Intra- day Precision for Metformin hydrochloride 
 
 
Morning 
Sr.No. Conc.(ppm) R.T.(Min) Area Result 
1 300 4.169 2880002 Mean = 2875798.66 
2 300 4.261 2871216 
3 300 4.208 2872495 S.D.= 4110.354 
Evening 4 300 4.195 2872531 
5 300 4.251 2879103 %R.S.D.= 0.14% 
6 300 4.250 2879445 
 
B. Intra- day Precision for Glipizide:- 
Table 10: Result of Intra- day Precision for Glipizide 
 
 
Morning 
Sr.No. Conc.(ppm) R.T.(Min) Area Result 
1 3 5.535 405362 Mean = 404558.66 
2 3 5.725 401759 
3 3 5.658 406520 S.D.= 2037.537 
Evening 4 3 5.700 406681 
5 3 5.698 402581 %R.S.D.= 0.50% 
6 3 5.698 404449 
 
. Inter- day Precision:- 
A. Inter- day Precision for Metformin hydrochloride:- 
Table 11: Result of Inter- day Precision for Metformin hydrochloride 
 
 
Day-1 
Sr.No. Conc.(ppm) R.T.(Min) Area Result 
1 300 4.169 2880002 Mean = 2878954.33 
2 300 4.261 2871216 
3 300 4.208 2872495 S.D.= 7320.294 
Day-2 4 300 4.203 2886219 
5 300 4.242 2875000 %R.S.D.= 0.25% 
6 300 4.454 2888794 
 
Inter- day Precision for Glipizide:- 
Table 12: Result of Inter- day Precision for Glipizide 
 
 
Day-1 
Sr.No. Conc.(ppm) R.T.(Min) Area Result 
1 3 5.535 405362 Mean = 403842.66 
2 3 5.725 401759 
3 3 5.658 406520 S.D.= 2137.702 
Day-2 4 3 5.653 401860 
5 3 5.690 402182 %R.S.D.= 0.529% 
6 3 6.119 405373 
 
 Linearity-  
Table 13: Linearity Data for Metformin Hydrochloride 
Sr.No. Concentration 
(µg/ml) 
RT (min) Area Plate Count 
1. 100 4.210 922877 8735 
2. 200 4.177 1894271 8800 
3. 300 4.169 2880002 8078 
4. 400 4.248 3871538 8836 
5. 500 4.250 4775306 8815 
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Figure 5: Linearity graph of Metformin HCl. 
Table 14: Linearity Data for Glipizide 
Sr.No. Concentration 
(µg/ml) 
RT (min) Area Plate Count 
1. 1 5.621 137246 8699 
2. 2 5.575 283287 8510 
3. 3 5.535 405362 8501 
4. 4 5.695 522726 8225 
5. 5 5.702 638980 8285 
 
 
Figure 6: Linearity graph of Glipizide. 
ROBUSTNESS: 
The robustness of an analytical method is a measure of its capacity to remain unaffected by small but deliberate variations in 
method parameters and provides an indication of its reliability during normal usage. 
 A] Change in Flow rate:- 
I) Metformin Hydrochloride - 
Table 15: Result and Statistical data of Robustness of Metformin Hydrochloride 
Sr.No. Conc.(µg/ml) Area of Peak λmax (nm) Flow rate (ml/min) Results 
1 200 1890209 226 0.7 Mean =1890623 
2 200 1887390 226 0.9 S.D =3459.16 
3 200 1894271 226 1.0 %S.D. =0.182 
 
II) Glipizide - 
Table 16: Result and Statistical data of Robustness of Glipizide 
Sr.No. Conc.(µg/ml) Area of Peak λmax (nm) Flow rate (ml/min) Results 
1 2 284705 226 0.7 Mean = 283529 
2 2 282596 226 0.9 S.D =1075.18 
3 2 283287 226 1.0 %S.D.=0.379 
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B] Change in Wavelength:- 
I) Metformin Hydrochloride - 
Table 17: Result and Statistical dada of Robustness of Metformin Hydrochloride 
Sr.No. Conc.(µg/ml) Area of Peak λmax (nm) Flow rate (ml/min) Results 
1 200 1894271 226 0.8 Mean = 1892893 
2 200 1893916 224 0.8 S.D = 2087.46 
3 200 1890491 228 0.8 %S.D. = 0.110 
 
II) Glipizide – 
Table 18: Result and Statistical dada of Robustness of Glipizide 
Sr.No. Conc.(µg/ml) Area of Peak λmax (nm) Flow rate (ml/min) Results 
1 2 283287 226 0.8 Mean =283140 
2 2 281458 224 0.8 S.D =1614.01 
3 2 284676 228 0.8 %S.D. = 0.570 
 
Ruggedness:- 
Table 19: Ruggedness Data for Metformin Hydrochloride 
Sr.No. Concentration 
(µg/ml) 
RT (min) Area Plate Count 
1. 100 4.135 925999 8431 
2. 200 4.173 1898856 8654 
3. 300 4.252 2888157 8380 
4. 400 4.241 3867325 8882 
5. 500 4.263 4772516 8288 
 
 
Figure 7: Ruggedness graph of Metformin Hydrochloride 
Table 20: Ruggedness Data for Glipizide 
Sr.No. Concentration (µg/ml) RT (min) Area Plate Count 
1. 1 5.533 137117 8385 
2. 2 5.573 283468 8495 
3. 3 5.703 408453 8965 
4. 4 5.686 527353 8573 
5. 5 5.723 638328 8456 
 
 
Figure 8: Ruggedness graph of Glipizide 
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Limit of Detection- 
The limit of detection (LOD) may be expressed as: -                                                            
                           LOD = 3.3 × (SD)/S 
Where, SD= Standard deviation of the Y intercept  
S = Slope  
A] LOD of Metformin Hydrochloride = 3.3 x 4932.68/ 
9682.1 = 1.68 (µg/ml). 
B] LOD of Glipizide = 3.3 x 2080.390/ 124291= 0.055 
(µg/ml). 
The LOD of Metformin Hydrochloride and Glipizide was 
found to be 1.68 (µg/ml) and 0.055 (µg/ml) respectively. 
 
Limit of Quantitation  
The quantitation limit (LOQ) may be expressed as  
          LOQ = 10 (SD)/S  
Where, SD = standard deviation of Y intercept  
S = Slope  
A] LOQ of Metformin Hydrochloride = 10 x 4932.68 / 
9682.1 = 5.09   (µg/ml). 
B] LOQ of Glipizide = 10 x 2080.390/124291= 0.167 
(µg/ml). 
The LOQ of Metformin Hydrochloride and Glipizide was 
found to be 5.09 (µg/ml) and 0.167 (µg/ml) respectively. 
Analysis of marketed formulation (Assay)- 
 
Table 21: Assay results 
Drug Label Claim 
(mg/tab) 
Taken Concentration 
(ppm) 
Area of  
Standard 
Area of 
sample 
% Assay 
Metformin Hydrochloride 500mg 300 ppm 2880002 2872186 99.72% 
Glipizide 5 mg 3 ppm 405362 405362 100% 
 
 
Figure 9: Chromatogram of Assay of Marketed Preparation 
  
SUMMARY AND CONCLUSION 
The present work involved the development of simple, 
accurate, precise and suitable RP-HPLC method. 
Literature survey revealed that several methods have been 
reported for determination of Metformin Hydrochloride and 
Glipizide individually or in combination with other drugs in 
pharmaceutical dosage forms.Hence,in the present study, a 
new, sensitive suitable and cost effective reversed-phase 
high performance liquid chromatography method was 
developed and validated for determination of Metformin 
Hydrochloride and Glipizide in bulk and pharmaceutical 
dosage form. 
In RP-HPLC method, the analytes were resolved by using 
isocratic program and mobile phase used was Methanol: 
Water (60:40 v/v; pH adjusted to 3 with OPA), at a flow rate 
of 0.8ml/min, in HPLC system containing UV-visible detector 
with HPLC workstation software and Cosmosil C-18 column 
(250 mm × 4.6 ID, particle size-5 micron) .The detection was 
carried out at 226 nm. The method gave the good resolution 
and suitable retention time. 
The results of analysis in the method were validated in terms 
of linearity, accuracy, precision, percent recovery, 
robustness, ruggedness, limit of detection and limit of 
quantitation. 
The method has several advantages, including simple mobile 
phase, low cost solvent, rapid analysis, simple sample 
preparation method and improved selectivity as well as 
sensitivity. The regression coefficient (R2) near to 1 which 
shows good linearity. The percent recovery was in the 
acceptable range in the tablet dosage form. The % RSD 
Values are also less than 2 %, showing high degree of 
precision of the proposed method. 
Since the method does not require use of expensive reagent 
and also less time consuming, it can be performed routinely 
in industry for routine analysis of marketed products of 
Metformin hydrochloride and Glipizide. 
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